Skip to main content


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Full Schedule

Full Schedule

  • Saturday, October 19, 2024
  • 8:15 AM – 9:15 AM  
    01 - The Use of HLA-Typed Cellular Transfusions and/or Infusions for In Vivo Adsorption of Donor-Specific HLA Antibodies (DSAs) as a Desensitization Strategy for Hematopoietic Stem Cell Transplant Patients
  • 8:15 AM – 9:15 AM  
    02 - Laboratory Clinicians and Transfusion Medicine Specialist at the center of patient safety
  • 8:15 AM – 9:15 AM  
    05 - RBC Transfusions for Patients with Hematologic Conditions: Hemoglobin Thresholds, Iron Metabolism
  • 8:15 AM – 9:15 AM  
    06 - Oral Abstract 12
  • 8:15 AM – 9:15 AM  
    07 - Preparing for the Data Deluge: Mitigating the Informatics Challenges of Expanded RBC Genotyping Data
  • 8:15 AM – 11:15 AM  
    08 - Enhance and Challenge Your Assessor Skills
  • 8:15 AM – 12:15 PM  
    04 - THOR AABB Joint Workshop
  • 9:45 AM – 10:45 AM  
    09 - Sterility Testing for Cellular Therapies: Updates and Challenges.  What should we be doing?
  • 9:45 AM – 10:45 AM  
    10 - Debate: Liberal versus Restrictive Transfusion Strategy in Acute Myocardial Infarction
  • 9:45 AM – 10:45 AM  
    11 - Coverage and Reimbursement Policy 101 for Transfusion Medicine and Cellular Therapies
  • 9:45 AM – 10:45 AM  
    12 - Discussion on the Application of Case-Based Learning in the Training of Postgraduate Trainees in Transfusion Medicine
  • 9:45 AM – 10:45 AM  
    13 - Oral Abstract - 13
  • 9:45 AM – 10:45 AM  
    14 - Validating the BECS
  • 11:15 AM – 12:15 PM  
    15 - Sickle Cell Disease Psychosocial Support and Advocacy
  • 11:15 AM – 12:15 PM  
    16 - Transfusion Support for Xenotransplantation
  • 11:15 AM – 12:15 PM  
    18 - ISBT/Joint Session
  • 11:15 AM – 12:15 PM  
    19 - Oral Abstract - 14
  • 11:15 AM – 12:15 PM  
    20 - Enhancing Laboratory Competency with AI: Meeting AABB Standards for Cell Processing Facilities and Blood Banks
  • 1:45 PM – 2:45 PM  
    21 - Critical Role of an Assay Lifecycle in Analytical Development for Cell and Gene Therapy Products
  • 1:45 PM – 2:45 PM  
    22 - Cryopreserved Platelets: From Bench to Bedside
  • 1:45 PM – 2:45 PM  
    23 - Ask the Standards
  • 1:45 PM – 2:45 PM  
    24 - Hemphill-Jordan Leadership Award
  • 1:45 PM – 2:45 PM  
    25 - Multidisciplinary Massive Transfusion Protocol Simulations: Updates and Best Practices in Simulation Science
  • 1:45 PM – 2:45 PM  
    26 - Oral Abstract 15
  • 1:45 PM – 2:45 PM  
    27 - Oral Abstract 16
  • Sunday, October 20, 2024
  • 8:15 AM – 9:15 AM  
    28 - The future of Cellular Therapy Using Mesenchymal Stromal Cells and Dendritic Cells
  • 8:15 AM – 9:15 AM  
    29 - New Directions in Coagulation Management and Transfusion Practice with Viscoelastic Testing in the OR
  • 8:15 AM – 9:15 AM  
    30 - What Does the Transfusion Service Need to do to Implement an ABO Incompatible Pediatric Heart Transplant Program?
  • 8:15 AM – 9:15 AM  
    32 - Ensuring Blood Availability for Mass Casualty Events
  • 8:15 AM – 9:15 AM  
    33 - Blood Donor Center Staffing Analysis – Armed Services Blood Program
  • 8:15 AM – 9:15 AM  
    34 - The Changing Landscape of Managing a Rare Blood Frozen Inventory
  • 8:15 AM – 3:00 PM  
    31 - SBB/BB Exam Review 2024
  • 9:30 AM – 11:00 AM  
    Plenary abstract Session
  • 2:00 PM – 3:00 PM  
    35 - Lesson's Learned Onboarding Cell and Gene Therapy Vendors and Clients in the 21st Century
  • 2:00 PM – 3:00 PM  
    36 - Point-of-care Transfusion Services With Remote, "Smart" Refrigerators Can Alleviate Laboratory Staffing Emergencies
  • 2:00 PM – 3:00 PM  
    37 - Why is My Blood Product Being Quarantined? Investigations that Happen Behind the Scenes.
  • 2:00 PM – 3:00 PM  
    38 - Diagnostic Blood Loss: An Ignored Component of the Multidisciplinary Pillar of Patient Blood management
  • 2:00 PM – 3:00 PM  
    39 - Sally Frank Memorial Award and Lectureship
  • 2:00 PM – 5:00 PM  
    40 - A Quality Bootcamp for Facility Compliance and Conformance to AABB Standards and Federal Regulations
  • 3:30 PM – 5:00 PM  
    41 - SICKLE CELL DISEASE: Inching towards Transfusion Independence. Exploring the journey from chronic transfusions to the novel biotherapeutics
  • 3:30 PM – 5:00 PM  
    42 - Transfusion Thresholds in Apheresis—Evidence or Art? Current Practice and Interactive Discussion
  • 3:30 PM – 5:00 PM  
    43 - Viral Vector Systems and Cellular Therapy
  • 3:30 PM – 5:00 PM  
    44 - Ultimate Test Your Blood Bank Knowledge 2024
  • 3:30 PM – 5:00 PM  
    45 - Beyond gender-based sexual activity blood safety rules - outcomes and next steps
  • 3:30 PM – 5:00 PM  
    46 - Transfusion Medicine, Hemostasis, Apheresis, and Cellular Therapy Review Session for Trainees
  • 3:30 PM – 5:00 PM  
    47 - Oral Abstracts 6
  • 3:30 PM – 5:00 PM  
    48 - Crisis in the rural hospital without access to blood transfusion: Innovative strategies to address global blood deserts and the Blood D.E.S.E.R.T. Coalition
  • Monday, October 21, 2024
  • 8:15 AM – 9:15 AM  
    49 - Source Plasma for Further Manufacture and Transfusion Medicine – Finding Common Ground
  • 8:15 AM – 9:15 AM  
    50 - A Multidisciplinary Approach to Delivering Comprehensive Care for Chronically Transfused Children and Adults with Sickle Cell Disease: An Overview of the Vanderbilt Sickle Cell Pathways Experience
  • 8:15 AM – 9:15 AM  
    51 - Clinical Relevance of ABO Antibodies and the New Era of Lectin Array Analysis of RBC ABO Glycosylation
  • 8:15 AM – 9:15 AM  
    52 - There’s a Blood Donation Bill Proposed to Require WHAT!?—Navigating the Legislative Proposal and Change Process
  • 8:15 AM – 9:15 AM  
    53 - Landsteiner-Alter Award and Lectureship
  • 8:15 AM – 9:15 AM  
    54 - Oral Abstract 5
  • 8:15 AM – 9:15 AM  
    55 - Oral Abstract 7
  • 8:15 AM – 12:15 PM  
    63 - CABP Exam Prep
  • 9:45 AM – 10:45 AM  
    56 - Management of Hematotoxicity from immune effector cell therapy and sickle cell disease gene therapy
  • 9:45 AM – 10:45 AM  
    57 - Should Rh Immune Globulin Be Administered After First Trimester Bleeding Events?
  • 9:45 AM – 10:45 AM  
    58 - Tibor Greenwalt Memorial Award and Lectureship
  • 9:45 AM – 10:45 AM  
    59 - Preventing Blood Product Tracking In a Mass Casualty Event from Becoming a Disaster
  • 9:45 AM – 10:45 AM  
    60 - Oral Abstract 4
  • 9:45 AM – 10:45 AM  
    61 - Oral Abstracts 8
  • 9:45 AM – 10:45 AM  
    62 - Innovation and Challenges in Donor Recruitment
  • 2:00 PM – 3:00 PM  
    64 - Mechanisms of Hematopoietic Stem Cells Towards Rejuvenation of the Aging Hematopoietic System
  • 2:00 PM – 3:00 PM  
    66 - What is Interventional Transfusion Medicine / Hemotherapy? Why It May Represent a New Future for Transfusion Medicine.
  • 2:00 PM – 3:00 PM  
    67 - Paradigm Changes in Transfusion Medicine – Disaster Preparedness
  • 2:00 PM – 3:00 PM  
    68 - What is the status of the U.S. Blood Supply? Preliminary findings of the 2023 National Blood Collection and Utilization Survey
  • 2:00 PM – 3:00 PM  
    69 - Oral Abstract 3
  • 2:00 PM – 3:00 PM  
    70 - Oral Abstract 9
  • 2:00 PM – 3:00 PM  
    71 - Emily Cooley Memorial Award and Lectureship (Awards)
  • 3:30 PM – 5:00 PM  
    65 - Choose Your Own Adventure: Exploring the Depths of Serology and Peaks of Genomics
  • 3:30 PM – 5:00 PM  
    72 - Overview of Cell-Based Biologics Manufacturing as a Contracted Service
  • 3:30 PM – 5:00 PM  
    73 - Ask the FDA
  • 3:30 PM – 5:00 PM  
    74 - Innovation in Transfusion: How Creative Partnerships are Improving the Care of Critically Ill Trauma Patients
  • 3:30 PM – 5:00 PM  
    75 - Solve It! Scenarios in Apheresis and Cellular Therapy
  • 3:30 PM – 5:00 PM  
    76 - Cell Therapy: Creative Inventory Management & Discard
  • 3:30 PM – 5:00 PM  
    77 - Lyophilized, Stem-cell Derived, and Synthetic Platelet products are closer than you may think.
  • 3:30 PM – 5:00 PM  
    78 - Oral Abstract 10 - Spotlight
  • 5:30 PM – 6:30 PM  
    79 - Mechanisms and Technologies Towards Expanding Hematopoietic Stem Cells for Transplantation
  • 5:30 PM – 6:30 PM  
    80 - The Role of Blood Operators and Transfusion Services in Preventing and Responding to Transfusion-transmitted Malaria
  • 5:30 PM – 6:30 PM  
    81 - Hemorrhage control and resuscitation: new tools.
  • 5:30 PM – 6:30 PM  
    82 - Turning Over Every Rock: Exploring Advanced Techniques in Platelet and Red Blood Cell Autoantibody Testing
  • 5:30 PM – 6:30 PM  
    83 - Oral Abstract 2
  • 5:30 PM – 6:30 PM  
    84 - Resilience Explored: Navigating Post-Pandemic Blood Products Utilization Trends and Supply Challenges in North America
  • Tuesday, October 22, 2024
  • 8:30 AM – 10:00 AM  
    85 - Beyond CAR T: Non-Conventional Applications of CAR Technology in Biotherapies
  • 8:30 AM – 10:00 AM  
    86 - Cross-cultural Conversations: Our Words and Interactions Have Power
  • 8:30 AM – 10:00 AM  
    87 - Addressing Racial Disparities Across Donation Products for Marginalized Peoples
  • 8:30 AM – 10:00 AM  
    88 - Blood Bank Guy Essentials LIVE!
  • 8:30 AM – 10:00 AM  
    89 - A Model to Improve Transfusion Quality Systems Worldwide: AABB (Association for the Advancement of Blood and Biotherapies -AMMTAC (Mexican Association of Transfusion Medicine, AC) International Partnership Chronicles
  • 8:30 AM – 10:00 AM  
    90 - Oral Abstract 17- Spotlight
  • 8:30 AM – 10:00 AM  
    91 - CSM Forum
  • 8:30 AM – 10:00 AM  
    92 - A Global Perspective of Roles, Responsibilities and Impact of Transfusion Safety Officers
  • 10:30 AM – 11:30 AM  
    16 - Coming to Terms with Changing Transfusion Practices in the NICU
  • 10:30 AM – 11:30 AM  
    93 - Duffy (ACKR1): Antibodies, Chemokines and Potential Therapeutic Targets-Not Just for Transfusion Anymore
  • 10:30 AM – 11:30 AM  
    94 - Is Your Firm Ready for an FDA Office of Regulatory Affairs Inspection? Hear about the Most Frequently Cited Observations and Inspectional Process from FDA’s Office of Biological Products Operations
  • 10:30 AM – 11:30 AM  
    95 - Managing Risk, Maximizing Safety: The Essentials of Proactive Risk Assessment
  • 10:30 AM – 11:30 AM  
    96 - Lord of the Antibodies
  • 10:30 AM – 11:30 AM  
    97 - In Limbo with ABO: The Type Discrepancies You’re Probably Seeing But No One is Talking About
  • 10:30 AM – 11:30 AM  
    98 - Oral Abstract 1
  • 10:30 AM – 11:30 AM  
    99 - Oral Abstract 11